• Exchange: NASDAQ GS
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Specialty Pharma

Enanta Pharmaceuticals Inc

+ Add to Watchlist


43.8600 USD 1.2800 3.01%

As of 20:10:00 ET on 08/27/2014.

Snapshot for Enanta Pharmaceuticals Inc (ENTA)

Open: 42.7900 Day's Range: 42.6000 - 44.2500 Volume: 391,710
Previous Close: 42.5800 52wk Range: 18.2500 - 46.4430 1-Yr Rtn: +134.92%

Stock Chart for ENTA

No chart data available.
  • ENTA:US 43.8950
  • 1D
  • 1M
  • 1Y
Interactive ENTA Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for ENTA

Current P/E Ratio (ttm) 24.7219
Estimated P/E(09/2014) 24.5852
Relative P/E vs. SPX 1.3745
Earnings Per Share (USD) (ttm) 1.7741
Est. EPS (USD) (09/2014) 1.7840
Est. PEG Ratio -
Market Cap (M USD) 815.03
Shares Outstanding (M) 18.58
30 Day Average Volume 187,096
Price/Book (mrq) 5.3281
Price/Sale (ttm) 17.4583
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 11/25/2014
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for ENTA

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for ENTA

Enanta Pharmaceuticals, Inc. manufactures pharmaceutical products. The Company develops, produces, and markets antibacterial drugs for hepatitis C virus, respiratory tract infections, intravenous, and oral treatments for hospitals and communities. Enanta Pharmaceuticals offers its products throughout the United States.

Jay R LulyPresident/CEONathaniel S Gardiner "Nat"Senior VP/General Counsel
Paul J MellettSenior VP:Finance/CFOTimothy D OcainSenior VP:New Product Strategy
More Company Profile & Key Executives for ENTA

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Sponsored Links
sec ||= nil